TY  - JOUR
AU  - Jänne, Pasi A
AU  - van den Heuvel, Michel M
AU  - Barlesi, Fabrice
AU  - Cobo, Manuel
AU  - Mazieres, Julien
AU  - Crinò, Lucio
AU  - Orlov, Sergey
AU  - Blackhall, Fiona
AU  - Wolf, Juergen
AU  - Garrido, Pilar
AU  - Poltoratskiy, Artem
AU  - Mariani, Gabriella
AU  - Ghiorghiu, Dana
AU  - Kilgour, Elaine
AU  - Smith, Paul
AU  - Kohlmann, Alexander
AU  - Carlile, David J
AU  - Lawrence, David
AU  - Bowen, Karin
AU  - Vansteenkiste, Johan
PY  - 2017
DO  - 10.1001/jama.2017.3438
UR  - http://hdl.handle.net/10668/11188
T2  - JAMA
AB  - There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer. To compare efficacy of the mitogen-activated protein kinase kinase (MEK) inhibitor...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Benzimidazoles
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Docetaxel
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Taxoids
KW  - Treatment Outcome
TI  - Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
TY  - research article
VL  - 317
ER  -